Title:  Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors

December 14, 11:00 AM

Speakers:

• Ursula A. Matulonis, MD, Dana-Farber Cancer Institute, USA
• Antonio González-Martín, MD, Clinica Universidad de Navarra, Spain
• Ignace Vergote, MD, UZ Leuven, Belgium

Program:

• Patient-specific and disease-specific factors that influence the prioritization of different PARP inhibitors – Dr. Matulonis
• Role of PARP inhibitor maintenance therapy in newly diagnosed ovarian cancer - Dr. Gonzalez-Martin
• PARP inhibitor-related adverse event identification and management – Dr. Vergote
• Future directions for PARP inhibitor therapy in frontline ovarian cancer – panel discussion